Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 42Lung Neoplasms 39Leukemia, Myeloid, Acute 36Carcinoma, Non-Small-Cell Lung 33Neoplasm Metastasis 29Breast Neoplasms 28Myelodysplastic Syndromes 20Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 19Pancreatic Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Multiple Myeloma 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 14Glioblastoma 14Carcinoma, Renal Cell 13Burkitt Lymphoma 13Squamous Cell Carcinoma of Head and Neck 12Urinary Bladder Neoplasms 10Melanoma 10Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Carcinoma, Hepatocellular 10Myeloproliferative Disorders 9Mouth Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Carcinoma 9Brain Neoplasms 9Oropharyngeal Neoplasms 8

Interventions

Nivolumab 2Magnetic Resonance Spectroscopy 2trastuzumab deruxtecan 1tamibarotene 1cabozantinib 1Ultrasonography 1Specimen Handling 1Ipilimumab 1Cisplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urethral Neoplasms × Specimen Handling × Clear all
NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡